Introducing a breakthrough dual overdose reversal drug.
Duversa can reverse overdoses of both opioids and tranquilizers, making it the first of its kind.
About Us
Scatr Medical builds upon the successful initiatives pioneered by Scatr. Leveraging our expertise in opioid and narcotic detection, we are now tackling the critical challenge of overdose reversal. Our mission is to innovate and implement life-saving solutions to combat the opioid crisis.
Technology
Scatr Medical has developed Duversa, a new overdose reversal formulation that may be more effective than naloxone for xylazine and fentanyl-xylazine overdoses. A pilot study on rats indicates Duversa could help address the rising public health issue of xylazine-related overdoses. Compared to naloxone, Duversa has been shown to:
Reduce the lethality of a fentanyl-xylazine overdoses by 50%.
Reverse fentanyl overdoses as effectively as naloxone.
Reduce xylazine overdose recovery time by 97%.
Drug Development Pipeline
News & Events
Biden-Harris administration
designates fentanyl combined with
xylazine as an emerging threat.
April 12, 2023
Construction sites in North America
are now required to have overdose
reversal drugs available on-site.
December 13, 2022
Public safety alert: DEA
reports widespread threat of
fentanyl mixed with xylazine.
November 8, 2022
© 2024 Scatr Medical Inc.